U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H14ClN3O4S
Molecular Weight 367.807
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFACLOR ANHYDROUS

SMILES

N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3

InChI

InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H14ClN3O4S
Molecular Weight 367.807
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CEFACLOR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes.

Launch Date

2002
Curative
CEFACLOR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes.

Launch Date

2002
Curative
CEFACLOR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes.

Launch Date

2002
Curative
CEFACLOR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes.

Launch Date

2002
Curative
CEFACLOR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes.

Launch Date

2002
Curative
CEFACLOR

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes.

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17.3 μg/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFACLOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17.5 μg × h/mL
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFACLOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.6 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CEFACLOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Hypersensitivity...
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Diarrhea...
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Eosinophilia, Pruritus genital...
Other AEs:
Eosinophilia (1 patient)
Pruritus genital (1 patient)
Moniliasis (1 patient)
Vaginitis (1 patient)
Sources:
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Aspartate aminotransferase increased, ALT increased...
Other AEs:
Aspartate aminotransferase increased (1 patient)
ALT increased (1 patient)
Sources:
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Alkaline phosphatase increased, Blood urea increased...
Other AEs:
Alkaline phosphatase increased (1 patient)
Blood urea increased (1 patient)
Sources:
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Other AEs: Creatinine serum increased...
20 mg/kg/day 3 times / day steady, oral
Dose: 20 mg/kg/day, 3 times / day
Route: oral
Route: steady
Dose: 20 mg/kg/day, 3 times / day
Sources:
unhealthy, pediatric
Other AEs: Reaction serum sickness-like...
AEs

AEs

AESignificanceDosePopulation
Hypersensitivity 1.5%
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Diarrhea 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Eosinophilia 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Moniliasis 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Pruritus genital 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Vaginitis 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
ALT increased 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Aspartate aminotransferase increased 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Alkaline phosphatase increased 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Blood urea increased 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Creatinine serum increased 1 patient
250 mg 3 times / day steady, oral
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
unhealthy, adult
Reaction serum sickness-like 0.5%
20 mg/kg/day 3 times / day steady, oral
Dose: 20 mg/kg/day, 3 times / day
Route: oral
Route: steady
Dose: 20 mg/kg/day, 3 times / day
Sources:
unhealthy, pediatric
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 1150 uM]
yes [Ki 65 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Oral pharmacokinetics of cefaclor in Mexican subjects.
2001
Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor.
2001 Dec
Etiologies of the urinary tract infections in a Yemeni City.
2001 Jul
Clinical and pro-host effects of cefaclor in prophylaxis of recurrent otitis media in HIV-infected children.
2001 Jul-Aug
Competition of IL-1 and IL-1ra determines lymphocyte response to delayed stimulation with PHA.
2001 Jun
Death from multi-resistant shigellosis in Fiji Islands.
2001 Mar
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution].
2001 May
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Antimicrobial susceptibility of nasopharyngeal isolates of Haemophilus influenzae from healthy children in day-care centres: results of multicentre study in Russia.
2001 Oct
Short-course therapy with cefaclor for treatment of streptococcal pharyngotonsillitis.
2001 Oct
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.
2001 Oct
Release profile of antimicrobial agents from alpha-tricalcium phosphate cement.
2001 Oct
[Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures].
2001 Sep
Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats.
2001 Sep
Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
2001 Sep-Oct
A comparative study of cefaclor vs. amoxicillin/clavulanate in tonsillopharyngitis.
2001 Sep-Oct
Levofloxacin: an updated review of its use in the treatment of bacterial infections.
2002
Immunoglobulin E binding determinants on beta-lactam drugs.
2002 Aug
Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan.
2002 Jan
Cutaneous and systemic manifestations of drug-induced vasculitis.
2002 Jan
Comparative study of cefaclor AF vs. cefuroxime axetil in acute exacerbations of chronic bronchitis.
2002 Jan
Foreign drug firm pleads guilty to felony charges.
2002 Jan-Feb
Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children.
2002 Jul
Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion.
2002 Jul
[Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999].
2002 Jun
The fecal microflora of 1-3-month-old infants during treatment with eight oral antibiotics.
2002 Jun
Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000.
2002 Jun
Trends in antimicrobial susceptibility of the Streptococcus milleri group.
2002 Jun
Serum sickness-like reactions.
2002 May
An evaluation of cefaclor in Pakistani children with pharyngotonsillitis.
2002 Oct
Cefaclor induced serum sickness like reaction.
2002 Oct
Mycobacterium bohemicum cervical lymphadenitis.
2002 Oct
The Italian Epidemiological Survey 1997-1999. Antimicrobial susceptibility data of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis in Italy.
2002 Oct
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000.
2002 Sep
Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor.
2002 Sep
Synthesis and biological activity of tris- and tetrakiscatecholate siderophores based on poly-aza alkanoic acids or alkylbenzoic acids and their conjugates with beta-lactam antibiotics.
2003
Drainage of liver abscess via laparoscopic trocar with local anesthesia.
2003 Apr
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.
2003 Apr
Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China.
2003 Aug
Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains.
2003 Feb
[In vitro sensitivity to antimicrobial agents of Haemophilus influenzae strains isolated from clinical specimens].
2003 Jan
[Antibiotic resistance and serotype distribution of Streptococcus pneumoniae strains isolated from patients at Hacettepe University Medical Faculty].
2003 Jan
Effect of extended-spectrum beta-lactamases on the susceptibility of Haemophilus influenzae to cephalosporins.
2003 Jan
Determination of cefaclor in human plasma by a sensitive and specific liquid chromatographic-tandem mass spectrometric method.
2003 Jan 25
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii.
2003 Jul
A comparative study of cefaclor vs amoxicillin/clavulanate in pediatric pharyngotonsillitis.
2003 Mar
Surveillance of antibiotic resistance in clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 2000-2001.
2003 Mar-Apr
[Report of questionnaire survey for methicillin-resistant Staphylococcus aureus and penisillin-resistant Streptococcus pneumoniae between 1998 and 2000 in the Kinki district].
2003 May
Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux.
2003 May
[Hypersensitivity reactions to beta-lactam antibiotics in childhood].
2003 May-Jun
Patents

Sample Use Guides

The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
Route of Administration: Oral
In Vitro Use Guide
Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:10 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:10 GMT 2025
Record UNII
3Z6FS3IK0K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFACLOR ANHYDROUS
Common Name English
CEFACLOR [MI]
Preferred Name English
Cefaclor [WHO-DD]
Common Name English
CEFACLOR IMPURITY C [EP IMPURITY]
Common Name English
cefaclor [INN]
Common Name English
CEFACLOR [JAN]
Common Name English
5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-, (6R,7R)-
Common Name English
(6R,7R)-7-(((2R)-2-AMINO-2-PHENYLACETYL)AMINO)-3-CHLORO-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000175488
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
WHO-ATC J01DC04
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NCI_THESAURUS C357
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
LIVERTOX NBK548666
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
NDF-RT N0000011161
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
LIVERTOX NBK548358
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
Code System Code Type Description
SMS_ID
100000092421
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
CAS
53994-73-3
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
INN
4086
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
FDA UNII
3Z6FS3IK0K
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
NCI_THESAURUS
C76033
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
CHEBI
3478
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
DAILYMED
3Z6FS3IK0K
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
EVMPD
SUB06163MIG
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
DRUG BANK
DB00833
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
RXCUI
1450910
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID3022748
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
WIKIPEDIA
Cefaclor
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
MERCK INDEX
m3184
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
258-909-5
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
PUBCHEM
51039
Created by admin on Mon Mar 31 18:07:10 GMT 2025 , Edited by admin on Mon Mar 31 18:07:10 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
TRANSPORTER -> INHIBITOR
Ki
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.
URINE
SOLVATE->ANHYDROUS
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY